This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The difference in costs between the two patients groups was tested using non-parametric tests.
Indirect Costs
The indirect costs of lost productivity were identified and included in the study. The resource use data (sick leave) were taken from the same patient sample that provided the clinical effectiveness evidence. Salary costs were estimated using data from Statistics Sweden. The price year was 2002.
Currency
Swedish kroner (SEK).
Sensitivity analysis
No sensitivity analysis was undertaken.
Estimated benefits used in the economic analysis
Not relevant.
Cost results
The total yearly cost was SEK 16,514 per person for the CBT group compared with SEK 45,990 for the information group, (p=0.06).
Synthesis of costs and benefits
Authors' conclusions
Cognitive-behavioural therapy (CBT) results in long-term health and economic benefits.
CRD COMMENTARY -Selection of comparators
The study compared the treatment of back pain with CBT with the provision of information to patients. This comparator was chosen as it represented usual practice in the authors' setting. This was not the only potential comparator intervention, thus you should consider how these treatments compare with usual practice in your own setting before applying the results of this study.
Validity of estimate of measure of effectiveness
The clinical effectiveness data were derived from an extension of a randomised controlled trial, which was an appropriate study design. The analysis appears to have been undertaken on a treatment completers only basis. Few details of the initial trial were provided in this paper, which means that it was difficult to assess its quality and hence the quality of the follow-on study. The authors did not compare the characteristics of their patient sample with the wider patient population, therefore it is not possible to comment on whether or not it was representative. These factors may limit the internal validity of the study findings.
Validity of estimate of measure of benefit
No measure of health benefit was combined with the economic data. The reader is referred to the comments in the 'Validity of estimate of measure of effectiveness' field (above).
